

SECOND EDITION



# **BIOTECHNOLOGY OPERATIONS**

**Principles and Practices**



**John M. Centanni • Michael J. Roy**



CRC Press  
Taylor & Francis Group

SECOND EDITION

# **BIOTECHNOLOGY OPERATIONS**

**Principles and Practices**

**John M. Centanni**  
**Michael J. Roy**




**CRC Press**

Taylor & Francis Group  
Boca Raton London New York

---

CRC Press is an imprint of the  
Taylor & Francis Group, an **informa** business

CRC Press  
Taylor & Francis Group  
6000 Broken Sound Parkway NW, Suite 300  
Boca Raton, FL 33487-2742



© 2017 by Taylor & Francis Group, LLC  
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper  
Version Date: 20160804

International Standard Book Number-13: 978-1-4987-5879-6 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access [www.copyright.com](http://www.copyright.com) (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

---

#### Library of Congress Cataloging-in-Publication Data

---

Names: Roy, Michael Joseph, author. | Centanni, John M., author.  
Title: Biotechnology operations : principles and practices / John M. Centanni and Michael J. Roy.  
Description: Second edition. | Boca Raton : CRC Press/Taylor & Francis, 2017.  
| Michael J. Roy's name appears first in the previous edition. | Includes bibliographical references and index.  
Identifiers: LCCN 2016034538 | ISBN 9781498758796 (hardback : alk. paper)  
Subjects: | MESH: Biotechnology--organization & administration | Biomedical Technology--organization & administration | Program Development  
Total Quality Management--methods | Planning Techniques  
Classification: LCC TP248.2 | NLM W 82 | DDC 660.6--dc23  
LC record available at <http://lccn.loc.gov/2016034538>

---

Visit the Taylor & Francis Web site at  
<http://www.taylorandfrancis.com>

and the CRC Press Web site at  
<http://www.crcpress.com>

Printed and bound in the United States of America by Sheridan

**SECOND EDITION**

# **BIOTECHNOLOGY OPERATIONS**

**Principles and Practices**

*Although our passion is in the expeditious development of biomedical products, it is also important to recognize the selflessness of research volunteers and patients who have the compassion and strength to participate in human clinical research studies for the betterment of others and in the hope of advancing medicine; without this, the development of new treatments would not be possible.*

---

## Preface

---

This book resulted from the authors' experiences gained while working in biotechnology development at industry, government, and academia, and while teaching a graduate course titled biotechnology operations. This course is offered to graduate students in the master of science (MS) in Biotechnology Program at the University of Wisconsin-Madison (<http://www.ms-biotech.wisc.edu/>). In this course, we examine the undertaking of developing biotechnology products, focusing on the scientific and management skills of biomanufacturing, clinical trials, nonclinical studies, project management, quality assurance, quality control, and regulatory affairs. The course emphasizes both operational planning for success and integration of plans and efforts in these seven functional areas. The instructors realized from their experience in the biotechnology industry the great need to carefully plan and fully integrate biotechnology development projects. The course is taught in that manner and this book reflects that philosophy; thus, this book is a practical guide for students and for those employed or interested in biotechnology.

This book is intended to meet a need and to fill a gap. Despite the wealth of experience with operations in the biotechnology industry, there was no single comprehensive and practical, yet fundamental, guide available. Many books and most individual scientific or trade publications are highly technical and focused on a specific aspect of biotechnology. They do not emphasize the themes of planning and integrating the seven operational endeavors. *Biotechnology Operations: Principles and Practices* is written with the objective of presenting a roadmap and reference for biotechnology operations, integrating these functional areas through the processes of product planning and design, and the practice of project management. It applies lessons learned in the biotechnology industry over past decades as novel products have been developed from emerging scientific discoveries. The lessons highlight development principles that could help the industry to bring to market more efficiently and quickly the safe and effective biotechnology products of the future. While focused largely on biopharmaceuticals, this book also reflects development of other biotechnology products. It is anticipated that this book will provide the reader a clear understanding of basic principles and practices, and assist in reducing risks and in resolving problems as future biotechnology discoveries are developed into products.

In preparation of the 2nd edition of this book, and at the request of the readers, we have enhanced our use of examples by including additional text boxes, diagrams, and figures. This 2nd edition now includes up-to-date methodologies associated with current biotechnology industry practices; incorporated are examples of tissue engineering, stem cell technologies, and the

use of alternative bioreactors. Chapter 2 now includes additional schematics to better depict abstract concepts. Chapter 3 is expanded to include current thinking of the FDA on various topics, and now includes specific information on submission formats and processes such as Common Technical Document format and electronic submissions. Chapters 2, 5, and 6 contain additional illustrations and examples of design and change control, management responsibilities, quality audit process, biomanufacturing facilities, whole animal bioreactors, and stem cell manufacturing processes. Chapter 7 is updated and includes depictions of testing equipment, figures outlining new concepts, and examples of trending and trend analysis. Chapter 8 now includes specific study design examples that have been used successfully to support translation of new biopharmaceutical products into human clinical trials. Finally, Chapter 9 includes an emphasis on the practical use of Good Clinical Practice (GCP) and how it directly applies to human clinical study management.

The target audience for this book is advanced undergraduates or postgraduate students pursuing an advanced degree in biotechnology and individuals working in any aspect of biotechnology product development. This book should be particularly relevant to students interested in biotechnology, biopharmaceutical product development, and those already working in biotechnology. The information presented in this book can be used to expand upon one's current experience while providing an additional level of appreciation and overview of the product development process. For those in the biotechnology industry, this book provides guidance on planning a new development program or managing an ongoing program. Noting that irrespective of the nature of the new biomedical product, the principles and practices outlined in this book are essential for the success of developing and marketing of a new product.



---

## Acknowledgments

---

The authors sincerely hope the experiences, ideas, and examples related in *Biotechnology Operations: Principles and Practices* will inspire the reader to plan and implement meaningful strategies and thereby expedite the development of desperately needed new medical products. Many of the examples and suggestions in this book represent challenges and successes that we've experienced throughout our careers. It is our passion to contribute ways that facilitate the transition of new therapies from the discovery or research environment into the clinic.

Special thanks go

- To the many students in the Master of Science in Biotechnology Program for helpful discussions and feedback on the best way to present this wealth of information.
- To Eric Schmuck and Derek J. Hei for their assistance with developing ideas and materials for this 2nd edition.
- To our many colleagues (especially Anthony [Tony] Clemento, Natalie Betz, and Edmund J. Elder Jr.) who have contributed to discussions and suggestions that made writing this book possible and also for their continued support and encouragement.

Our special thanks go to Kurt Zimmerman, program director of the Master of Science in Biotechnology Program at the University of Wisconsin-Madison, for his continuing support and for providing a program in which the students are trained and encouraged to become industry leaders.



---

## Authors

---

**John M. Centanni, MS**, has a faculty associate appointment in the School of Medicine and Public Health at the University of Wisconsin-Madison, in the Master of Science in Biotechnology Program. He has firsthand experience of leading functional groups in biotechnology firms as a project manager. His strong scientific background has allowed him to serve multiple scientific R&D roles in the biotech industry contributing to the development of pre-clinical safety studies, quality control assays, and animal models. Centanni has participated in the development and implementation of quality systems to meet regulatory compliance in both the industry and academic environments. He has directly overseen the regulatory and clinical operations associated with a number of early phase, multicenter, human clinical trials. Centanni has worked in the pharmaceutical and biotechnology industry since 1987 and has more than 20 years of product development experience for drugs, biologics, and devices. He has instructed and trained basic scientists and clinical researchers in regulatory compliance and expectations associated with clinical product development (Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), and Good Tissue Practice (GTP), and Good Clinical Practice). Centanni is experienced in preclinical research, regulatory, quality, clinical development, and project management, and has been involved in the development and registration of pharmaceutical products across a number of therapeutic categories.

Centanni is the director of the Investigational New Drug (IND)/Investigational Device Exemption (IDE) Consultation Services, where he leads a team of consultants at the University of Wisconsin-Madison, Institutes for Clinical and Translational Research. In this role, he provides campus-wide support to clinical investigators advancing their investigational product from the research environment into the clinic. This support ranges from strategic support for the selection of viable product development candidates to characterization of products and design and implementation of human clinical trials.

Centanni is also an active participant in the Stem Cell and Regenerative Medicine Center and Cardiovascular Regeneration Focus Group at the University of Wisconsin. He serves on a number of grant review panels that include California Institute for Regenerative Medicine (CIRM), Institute for Clinical and Translational Research (ICTR) Novel Therapeutics Pilot Awards, and American Burn Association (ABA) Multicenter Clinical Trials Group.

Before joining the University of Wisconsin, Centanni directed the regulatory, quality, and clinical efforts of a small biotechnology firm in Madison, Wisconsin. As an accomplished molecular and cellular biologist, Centanni has successfully directed multimillion dollar translational and clinical

research projects as principal investigator. Additional professional attributes of Centanni include a notable patent portfolio as an inventor on more than a half dozen intellectual property filings and authorship of several scientific journal articles and book chapters.

Centanni is a graduate of Hood College, Frederick, Maryland, with a master's degree in biomedical sciences supported by a thesis and defense. Prior to graduate school, Centanni earned a BS in biology at the University of Wisconsin-Oshkosh, Wisconsin. In his free time, Centanni enjoys saltwater fishing, snorkeling, traveling, and playing racquet ball.

**Michael J. Roy, PhD**, is an emeritus professor at the University of Wisconsin-Madison, where he previously taught in the Master of Science in Biotechnology Program in the School of Medicine and Public Health. He has successfully developed biopharmaceutical products and medical devices for private and publically held firms, nongovernmental organizations, and the federal government for more than 27 years, serving as a consultant in biotechnology development over the past decade. Many of his efforts, including product development planning, regulatory affairs, quality systems, project management, biomanufacturing, quality control, and clinical studies, focus on early development of novel biotechnology products, notably vaccines and antimicrobial agents.

He is a graduate of the University of Wisconsin-Madison with a PhD in pathology, of Louisiana State University Medical Center, New Orleans, with an MS in tropical medicine and medical parasitology, and of the University of Wisconsin-Platteville with a BS in biology. Colonel Roy is retired from the U.S. Army Reserves, where he was involved in developing in vitro diagnostic devices and vaccines and in establishing quality systems at the U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick. He also enjoys hiking, raising hardwood trees in southwestern Wisconsin, and has archeological interests of that region.

---

# Contents

---

Preface.....xv

Acknowledgments ..... xvii

Authors ..... xix

**1. Introduction to Biotechnology Operations: Planning for Success..... 1**

    Biotechnology Operations ..... 1

    Marketing, Financial, and Business Considerations for Development ....4

    Product Development Planning .....7

        Rationale for Product Development Planning.....7

        The Targeted Product Profile ..... 10

        The Product Development Plan..... 16

            Clinical Development Planning..... 18

            Project Management Planning..... 19

            Regulatory Planning.....20

            Nonclinical Planning.....22

            Biomanufacturing Planning.....23

            Quality Control Planning ..... 24

            Quality Systems and Quality Assurance Planning ..... 26

            Additional Elements of Product Planning ..... 26

    Summary of Planning for Success ..... 28

**2. Project Management ..... 29**

    Biotechnology and Project Management..... 29

    Background of Project Management..... 31

    Project Management Plan..... 32

        The Project Management Environment..... 34

        Project Objectives and Schedules ..... 36

        Sociotechnical Considerations ..... 37

        Participants in Project Management ..... 37

    Project Management in Biotechnology Operations ..... 41

        Establishing Project Management ..... 41

        The Work Breakdown Structure ..... 42

        Forming a Project Team and Hands-on Project Management ..... 46

        Team Dynamics..... 46

        Communication and Feedback ..... 49

        Project Risk Assessment and Management ..... 51

        Metrics and Tracking Progress ..... 53

        Resources: Planning and Usage..... 54

        Human Factors in Project Management ..... 55

        Project Completion..... 57

Project Management with Contracts and Collaborations .....	59
Virtual Teams .....	60
Tools for Effective Project Management .....	61
Summary of Project Management in Biotechnology Development .....	64
<b>3. Regulatory Affairs .....</b>	<b>65</b>
The U.S. Food and Drug Administration: Law and Regulations for Biopharmaceuticals .....	65
Historical Basis for FDA Regulation .....	65
Regulatory Organization of the FDA .....	66
Food and Drug Law, Regulation, and Guidance .....	71
FDA-Regulated Products .....	71
Biologics .....	72
Drugs .....	75
Medical Devices .....	76
Combination Products .....	77
Other Classes of Biotechnology Products and Their Review at the FDA .....	79
Products for Veterinary Use .....	79
Cosmetics, Food, Dietary Supplements, Homeopathic, or Nutritional Products .....	79
FDA Regulatory Information and Resources: Regulatory Intelligence .....	81
Regulatory Operations for FDA Applications .....	84
Regulatory Planning and the Regulatory Environment .....	84
Risk Versus Benefit .....	84
Applications Seeking FDA Investigational Use or Marketing Approval .....	87
Investigational Use Applications. The Investigational New Drug Application .....	89
Common Technical Document .....	91
Electronic Submission of a CTD .....	92
Marketing Applications: BLA and NDA .....	96
Medical Device Applications. 510(k) and PMA .....	99
Special Documents, Pathways, or Exemptions .....	101
Generic Drugs and Biosimilar or Follow-on Biologics .....	104
Other Regulatory Activities .....	105
Public Meetings and Advisory Committees .....	105
Postmarketing Requirements and Activities .....	107
Advertising and Promotion .....	108
Summary of Regulatory Affairs Activities in Biotechnology Operations .....	109
References .....	111

**4. Regulatory Compliance**..... 113

Regulatory Compliance ..... 113

Quality Systems to Meet Regulatory Compliance ..... 113

    Compliance and Quality Systems ..... 113

    Current Good Manufacturing Practices for Manufacture and  
    Quality Control ..... 114

    Current Good Laboratory Practices for Nonclinical Laboratory  
    Studies ..... 117

    Current Good Clinical Practices for Clinical Studies ..... 117

Compliance for Biopharmaceuticals: Other Regulations of  
Importance ..... 119

    Compliance for Import of Biopharmaceuticals into the  
    United States ..... 119

    Compliance for Medical Devices ..... 120

Inspection and Enforcement ..... 120

    Inspections ..... 121

    Enforcement Actions ..... 123

    Product Liability..... 125

Compliance with Non-FDA Regulations: International, National,  
State, and Local ..... 126

    International and Foreign National Regulatory Authorities for  
    Medical Biotechnology Products ..... 126

    Transporting Infectious or Otherwise Hazardous Materials..... 132

    Importing, Possessing, or Transferring Controlled  
    Biotechnology Materials ..... 134

    The Public Health Security and Bioterrorism Preparedness and  
    Response Act of 2002 ..... 136

    Importation or Exportation of Biotechnology Products for the  
    Purpose of Treatment of Diseases in Humans ..... 137

    Occupational Health and Safety ..... 140

    Environmental Regulations in Biotechnology..... 141

    Genetically Modified Organisms or Molecules..... 142

    International Diligence in Biotechnology Operations..... 144

Summary of Regulatory Compliance ..... 146

    Summary of Non-FDA Compliance..... 147

References ..... 148

**5. Quality Systems**..... 149

Overview of Quality in Biotechnology..... 149

History: Evolution of Quality Concepts and Practices..... 150

Quality Systems Approach to Product Development ..... 153

Planning a Quality System..... 156

    Defining Objectives and Ensuring Management Support..... 156

    The Quality Manual ..... 156

    The Quality Plan ..... 157

Hallmarks of Quality: Fundamental Criteria for Building Effective Quality Systems .....	159
Management Responsibility .....	160
Defined Quality System .....	162
QbD and Design Control .....	163
Quality by Design .....	163
Design Control .....	164
Design Change .....	169
Contractor, Vendor, and Consultant Control .....	169
Product Identification and Traceability .....	171
Process Control .....	172
Environmental Controls .....	173
Inspection or Testing (Quality Control) .....	173
Release of Material, Service, or Product .....	174
Change Control and Corrective or Preventive Actions .....	175
Packaging and Labeling .....	176
Preservation, Storage, and Handling .....	176
Servicing .....	178
Customer Concerns and Adverse Event Reports .....	178
Document Control .....	178
Training .....	178
Auditing .....	179
The Quality Assurance Unit .....	180
Manage the Quality Assurance Function .....	181
Control Documents and Manage the Documentation System .....	182
Investigate Situations: Manage and Control Change .....	184
Ensure Qualified and Trained Staff .....	184
Perform Audits .....	185
Initiate a Quality System for a Biotechnology Operation .....	188
Unique and Effective Approaches to Quality Management .....	190
Risk-Based Approaches to Quality Systems .....	190
Total Quality Management .....	190
Six Sigma .....	191
Statistics in Quality Assurance .....	191
Quality Systems for Research .....	191
Resolving Quality Issues or Problems .....	192
Summary of Quality Systems .....	193
References .....	194
<b>6. Biomanufacture .....</b>	<b>195</b>
Overview of Biomanufacturing Requirements .....	195
Design in Biomanufacture .....	196
Technical Considerations for Biomanufacture .....	200
Phases and Scale-up: The Biomanufacturing Life Cycle .....	201
Raw Material Considerations .....	205

Compliance and Quality in Biomanufacture: Current Good  
Manufacturing Practices..... 207

Biomanufacturing Processes for Biotechnology Products..... 209

    Expression of Recombinant Proteins and Nucleic Acids ..... 209

        Production of Recombinant Molecules from Expression  
            Vectors..... 209

            Genes, Vectors, and Host Cells..... 210

            Bacterial Cell Expression Systems ..... 212

            Yeast Cell Expression Systems ..... 213

            Mammalian or Insect Cell Expression Systems ..... 213

        Production of Master Cell Banks and Working Cell Banks..... 216

    Biomanufacture of Recombinant Proteins ..... 217

        Planning Production of a Recombinant Protein..... 217

        Upstream Process: Production by Bacterial or Yeast Cell  
        Fermentation..... 218

        Upstream Process: Production by Mammalian or Insect  
        Cell Culture..... 220

        Upstream Process: Recovery ..... 221

        Downstream Process: Purification ..... 222

    In-Process Testing and Analysis of Bulk Substance ..... 230

    Production of Bacterial Plasmid DNA ..... 231

    Production of Live Recombinant Organisms: Bacteria and Virus... 232

    Production of Products Composed of Mammalian Somatic  
    Cells or Tissues..... 234

    Production of Cellular Products Derived from Pluripotent  
    (Stem) Cells..... 236

    Production of Biological Molecules by Transgenic Animals or  
    Plants..... 238

    Production of Biologically Active Lipids, Glycolipids, and  
    Complex Carbohydrates..... 245

    Production of Biologically Active Peptides ..... 245

    Production of Combination Products: Biopharmaceutical with  
    a Drug or Medical Device..... 247

FP: Formulation, Fill, Finish, and Labeling..... 248

Biomanufacturing Facilities, Utilities, and Equipment..... 253

    Facility Design Considerations ..... 253

    The Facility and Utilities: A Controlled Environment ..... 254

    Operation of Clean Work Areas for Biomanufacture ..... 255

    Biomanufacturing Equipment ..... 257

Contract Manufacturing Options..... 257

Validation of Biomanufacturing Facilities, Utilities, Equipment,  
and Processes ..... 259

Summary of Biomanufacture..... 261

References ..... 262



<b>7. Quality Control</b>	263
Quality Control Overview	263
Definition of Product Attributes	265
Analytical Methods to Measure Attributes	266
Traits of Analytical Methods	267
Drafting a Certificate of Analysis (Bulk Substance)	267
Selection of Analytical Methods	270
Development of Specifications	277
Entering Test Results	282
Certificate of Analysis for Drug Product	282
In-Process Testing	285
Analytical Methods	286
Additional Analytical Tools and Concepts	295
Quality Control of Cell Banks	297
Samples and Sampling	298
Analytical Controls and Reference Standards	299
Test Failures, Out-of-Specification Results, and Retesting	300
Testing for Product Stability	302
Quality Control Testing of Raw Materials	308
Quality Control and the Manufacturing Environment	310
Qualification, Validation, and Verification of Analytical Methods	312
Application of Statistics in Assay Performance and Validation	317
Summary of Quality Control	318
References	319
<b>8. Nonclinical Studies</b>	321
Nonclinical Studies and Risk Assessment	321
Biopharmaceutical Delivery, Pharmacokinetics, and Pharmacodynamics	323
Product Delivery to the Body	323
Adsorption, Distribution, Elimination, and Metabolism (ADME)	325
Absorption	325
Distribution	325
Metabolism and Biotransformation	327
Excretion	328
Pharmacokinetics and Pharmacodynamics	328
Application of Pharmacokinetics and Pharmacodynamics in Biopharmaceutical Development	333
Safety Assessment of Biopharmaceuticals	336
Toxicology	336
Design of a Safety Assessment Program	337
In Vitro Screens: Surrogate Measures of Toxicity	340

In Vivo Safety Testing of Biopharmaceuticals .....342

    Animal Model Development.....342

    Test Product Formulations, Routes of Delivery, and Dosing  
    Designs .....344

Protocols and Performance of Biopharmaceutical Safety Studies  
in Animals.....346

Elements of a Nonclinical Study Design .....347

Nonclinical Safety Testing.....351

Acute Toxicity Testing .....351

Subchronic and Chronic Toxicity Testing .....356

Reproductive, Developmental, and Teratogenicity Toxicity  
Testing.....359

Carcinogenicity Testing .....360

Immunotoxicology.....361

Genetic Toxicology.....363

Tissue Binding or Local Tissue Tolerance .....367

Quality of Nonclinical Studies: Current Good Laboratory Practices..... 368

Summary of Nonclinical Studies .....369

References .....370

**9. Clinical Trials.....371**

    Introduction to Clinical Trials.....371

    Background of Clinical Research .....373

        Introduction .....373

        Historical Information on Clinical Trials .....374

    Organization of Clinical Research .....375

        Phases of Clinical Trials.....375

        The Science of Clinical Research .....376

        Quality in Clinical Research and Current Good Clinical Practices..... 377

        Clinical Development Planning.....377

    Infrastructure for a Clinical Trial: Individuals, Documents, and  
    Investigational Product.....378

        Design of Clinical Trials and the Clinical Protocol.....378

        Human Subjects, Patients, and Volunteers.....388

        The Sponsor .....388

        The Principal Investigator and His or Her Study Staff .....391

        Institutional Review Boards, the Process of IC, and IC Form .....392

        Investigational Product .....394

        Collection of Clinical Data: Case Report Forms and the Patient  
        Diary .....395

        Clinical Testing Laboratories.....396

        Reporting Results of Clinical Trials: Clinical Summary Reports....397